| EGLE, Alexander, Thomas MELCHARDT, Petra OBRTLIKOVA, Lukas SMOLEJ, Tomas KOZAK, Michael STEURER, Johannes ANDEL, Sonja BURGSTALLER, Eva MIKUSKOVA, Liana GERCHEVA, Thomas NOSSLINGER, Tomas PAPAPJIK, Miriam LADICKA, Michael GIRSCHIKOFSKY, Mikulas HRUBISKO, Ulrich JAGER, Daniela VOSKOVA, Martin PECHERSTORFER, Eva KRALIKOVA, Christina BURCOVEANU, Emil SPASOV, Andreas PETZER, Georgi MIHAYLOV, Julian RAYNOV, Horst OEXLE, August ZABERNIGG, Emilia FLOCHOVA, Stanislav PALASTHY, Olga STEHLÍKOVÁ, Michael DOUBEK, Petra ALTENHOFER, Lukas WEISS, Teresa MAGNES, Lisa PLEYER, Anton KLINGLER, Jiří MAYER and Richard GREIL. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine. Houston: John Wiley & Sons Ltd., 2019, vol. 8, No 4, p. 1401-1405. ISSN 2045-7634. Available from: https://dx.doi.org/10.1002/cam4.1980. |
Other formats:
BibTeX
LaTeX
RIS
@article{1548863,
author = {Egle, Alexander and Melchardt, Thomas and Obrtlikova, Petra and Smolej, Lukas and Kozak, Tomas and Steurer, Michael and Andel, Johannes and Burgstaller, Sonja and Mikuskova, Eva and Gercheva, Liana and Nosslinger, Thomas and Papapjik, Tomas and Ladicka, Miriam and Girschikofsky, Michael and Hrubisko, Mikulas and Jager, Ulrich and Voskova, Daniela and Pecherstorfer, Martin and Kralikova, Eva and Burcoveanu, Christina and Spasov, Emil and Petzer, Andreas and Mihaylov, Georgi and Raynov, Julian and Oexle, Horst and Zabernigg, August and Flochova, Emilia and Palasthy, Stanislav and Stehlíková, Olga and Doubek, Michael and Altenhofer, Petra and Weiss, Lukas and Magnes, Teresa and Pleyer, Lisa and Klingler, Anton and Mayer, Jiří and Greil, Richard},
article_location = {Houston},
article_number = {4},
doi = {http://dx.doi.org/10.1002/cam4.1980},
keywords = {BMI; CLL; maintenance; obesity; rituximab},
language = {eng},
issn = {2045-7634},
journal = {Cancer Medicine},
title = {Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial},
url = {http://dx.doi.org/10.1002/cam4.1980},
volume = {8},
year = {2019}
}
TY - JOUR
ID - 1548863
AU - Egle, Alexander - Melchardt, Thomas - Obrtlikova, Petra - Smolej, Lukas - Kozak, Tomas - Steurer, Michael - Andel, Johannes - Burgstaller, Sonja - Mikuskova, Eva - Gercheva, Liana - Nosslinger, Thomas - Papapjik, Tomas - Ladicka, Miriam - Girschikofsky, Michael - Hrubisko, Mikulas - Jager, Ulrich - Voskova, Daniela - Pecherstorfer, Martin - Kralikova, Eva - Burcoveanu, Christina - Spasov, Emil - Petzer, Andreas - Mihaylov, Georgi - Raynov, Julian - Oexle, Horst - Zabernigg, August - Flochova, Emilia - Palasthy, Stanislav - Stehlíková, Olga - Doubek, Michael - Altenhofer, Petra - Weiss, Lukas - Magnes, Teresa - Pleyer, Lisa - Klingler, Anton - Mayer, Jiří - Greil, Richard
PY - 2019
TI - Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial
JF - Cancer Medicine
VL - 8
IS - 4
SP - 1401-1405
EP - 1401-1405
PB - John Wiley & Sons Ltd.
SN - 20457634
KW - BMI
KW - CLL
KW - maintenance
KW - obesity
KW - rituximab
UR - http://dx.doi.org/10.1002/cam4.1980
L2 - http://dx.doi.org/10.1002/cam4.1980
N2 - No data are available regarding obesity and outcome in Chronic Lymphocytic Leukemia (CLL). We analyzed 263 patients from the AGMT CLL-8a Mabtenance trial for the impact of obesity. The trial included patients after rituximab-containing induction treatment in first or second line that had achieved at least a PR. A randomization to rituximab maintenance treatment (375mg/m(2) q3 months for 2years) vs observation was performed. In this cohort 22% of the patients (58/263) were classified as obese. The baseline response to induction treatment was inferior in obese patients with a lower CR rate (43.1% vs 60.5% in obese vs non-obese, P=0.018) and with a lower rate of patients achieving MRD negativity after chemoimmunotherapy induction treatment (19.6% vs 35.8%, P=0.02). The PFS outcome of obese patients was significantly worse in the observation group of the trial (24 vs 39months median PFS, P=0.03). However, in the rituximab maintenance group the outcome for obese vs non-obese was not different (P=0.4). In summary, obesity was overall associated with a worse outcome of chemoimmunotherapy induction. However, rituximab maintenance treatment seems to be able to overcome this negative effect.
ER -
EGLE, Alexander, Thomas MELCHARDT, Petra OBRTLIKOVA, Lukas SMOLEJ, Tomas KOZAK, Michael STEURER, Johannes ANDEL, Sonja BURGSTALLER, Eva MIKUSKOVA, Liana GERCHEVA, Thomas NOSSLINGER, Tomas PAPAPJIK, Miriam LADICKA, Michael GIRSCHIKOFSKY, Mikulas HRUBISKO, Ulrich JAGER, Daniela VOSKOVA, Martin PECHERSTORFER, Eva KRALIKOVA, Christina BURCOVEANU, Emil SPASOV, Andreas PETZER, Georgi MIHAYLOV, Julian RAYNOV, Horst OEXLE, August ZABERNIGG, Emilia FLOCHOVA, Stanislav PALASTHY, Olga STEHLÍKOVÁ, Michael DOUBEK, Petra ALTENHOFER, Lukas WEISS, Teresa MAGNES, Lisa PLEYER, Anton KLINGLER, Jiří MAYER and Richard GREIL. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. \textit{Cancer Medicine}. Houston: John Wiley \&{} Sons Ltd., 2019, vol.~8, No~4, p.~1401-1405. ISSN~2045-7634. Available from: https://dx.doi.org/10.1002/cam4.1980.
|
